Results 11 to 20 of about 5,702,542 (372)
Blood Cancer Journal, 2022 We here defined the impacts of γ-secretase inhibitors (GSIs) on T-cell-dependent BCMA-specific multiple myeloma (MM) cell lysis and immunomodulatory effects induced by bispecific antibodies (BisAbs).
Hailin Chen +13 more
doaj +1 more source
Journal of the American Medical Association (JAMA), 2022 What Is Multiple Myeloma? Cancer starts when cells begin to grow out of control. Cells in nearly any part of the body can become cancer, and can spread to other areas.
Juliet Silberstein +2 more
semanticscholar +1 more source
Epidemiology, Staging, and Management of Multiple Myeloma
Medical Science, 2021 Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world, especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2% of cancer diagnoses and over 2% of cancer deaths (more than double the ...
S. Padala +7 more
semanticscholar +1 more source
Nature Communications, 2021 BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and durable responses in multiple myeloma. However, relapse following therapy is frequently observed, and mechanisms of resistance remain ill-defined.
M. Samur +14 more
semanticscholar +1 more source
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
Cancers, 2021 Simple Summary Multiple Myeloma (MM) is a hematologic malignancy caused by aberrant plasma cell proliferation in the bone marrow (BM) and constitutes the second most common hematological disease after non-Hodgkin lymphoma.
A. García-Ortiz +6 more
semanticscholar +1 more source
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
American journal of hematology/oncology, 2020 Multiple myeloma accounts for approximately 10% of hematologic malignancies.
S. Rajkumar
semanticscholar +1 more source
Cancer Medicine, 2022 Background Maintenance therapy with proteasome inhibitors (PIs) can improve outcomes of multiple myeloma (MM) patients, however, the neurotoxicity and parenteral route of bortezomib limit its long‐term use.
Man Shen +8 more
doaj +1 more source
Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation
Blood Cancer Journal, 2021 MYC upregulation is associated with multidrug refractory disease in patients with multiple myeloma (MM). We, isolated patient-derived MM cells with high MYC expression and discovered that NCOR2 was down-regulated in these cells.
Tomoaki Mori +13 more
doaj +1 more source
Selinexor: Targeting a novel pathway in multiple myeloma
eJHaem, 2023 Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nuclear proteins to
Clifton C. Mo +9 more
doaj +1 more source